Followers | 18 |
Posts | 2369 |
Boards Moderated | 0 |
Alias Born | 01/09/2012 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, December 27, 2013 1:24:56 PM
Go to this TEVA link blow:
http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-reportsAnnual
Look for the Excel document about half way down the page called "Historic Sales by Branded Products", open it up and you will see that TEVA's generics have been steadily declining: 2011 Y/Y growth of 3%; 2012 Y/Y growth of 2%; and after 3 quarters in 2013 the Y/Y growth is 0%.
That's why TEVA is dumping these generics and they will probably continue to unload some others. NOTE: keep in mind these are SALES figures, NOT, net profit figures!
But just for the sake of argument and to not be totally negative here, go to this TEVA link
http://www.tevapharm.com/Products/Pages/default.aspx
You will note under the section called, "Generic Products", TEVA claims to have approximately 20% of the generic market in the US. If we now assume that TEVA had 20% of the $860 million market that would be equivalent to about $172 million market for these 31 generics. However, we know that TEVA will get royalties and so if we use a reasonable 25% royalties goes to TEVA, leaves a market of $129 million as the BEST CASE scenario of market share to ANIP.
I say that this is best case because we are assuming that TEVA had 20% of the market for these 31 generics but in reality it was probably a bit lower as my assumption is that TEVA would unload its lower market share generics while keeping the higher market share generics. A more reasonable estimate would probably be 10%-20% and after removing the 25% royalty would leave ANIP with an estimated peak revenue of $64 million to $129 million before costs, taxes, etc.
Now, the fact that TEVA's latest 2013 Y/Y sales growth for generics was 0% means these products are probably stagnant and there's no more growth left in them. Also, keep in mind that generics are much less profitable than branded drugs and so it is likely that these specific generic products were probably amongst TEVA's lowest profitable generics.
This is all imo but I think this is a reasonable analysis and we haven't even talked about the amount of funding that ANIP will need to get all 31 generics out the door!
CAUTION: Do NOT rely on information from ShortAnalytics - it is unreliable because the total volume is inaccurate!
Recent ANIP News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 12:29:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:21:44 PM
- ANI Pharmaceuticals, Inc. Closes $316.25 Million Convertible Senior Notes Offering Including Full Exercise of Initial Purchasers’ Option to Purchase Additional Notes • GlobeNewswire Inc. • 08/13/2024 08:05:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 01:51:52 AM
- ANI Pharmaceuticals, Inc. Prices Upsized $275.0 Million Convertible Senior Notes Offering • GlobeNewswire Inc. • 08/08/2024 01:44:18 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 11:26:24 AM
- ANI Pharmaceuticals, Inc. Announces Proposed Convertible Senior Notes Offering • GlobeNewswire Inc. • 08/07/2024 11:00:55 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 10:57:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 10:53:07 AM
- ANI Pharmaceuticals Reports Second Quarter 2024 Financial Results and Raises 2024 Guidance • GlobeNewswire Inc. • 08/06/2024 10:50:00 AM
- ANI Pharmaceuticals to Discuss Second Quarter 2024 Financial Results on August 6, 2024, at 8:30 a.m. ET • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/19/2024 09:30:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/19/2024 09:27:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/18/2024 09:12:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 11:07:47 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/17/2024 08:41:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/16/2024 09:37:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/15/2024 08:57:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 08:38:14 PM
- ANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral Powder • GlobeNewswire Inc. • 07/15/2024 11:00:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/12/2024 08:17:12 PM
- ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP • GlobeNewswire Inc. • 07/02/2024 11:00:00 AM
- ANI Pharmaceuticals’ CEO Nikhil Lalwani Named EY Entrepreneur Of The Year® 2024 New Jersey Award Winner • GlobeNewswire Inc. • 06/25/2024 11:00:02 AM
- ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences • GlobeNewswire Inc. • 06/24/2024 10:50:44 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/18/2024 08:37:33 PM
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM
Reliant Coffee Debuts at #271 on the Inc. 5000 List of Fastest Growing Companies - Coffee Service Industry Disruptor Brews Up Exponential Growth Sep 5, 2024 11:51 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • MFL • Sep 4, 2024 9:02 AM
Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • INTV • Sep 4, 2024 8:45 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM